Regulatory approval

Published by the Health Service Executive. Approved

Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease.

This is written in the approval document.

Reimbursement

CDS

Citation

Vandetanib Therapy, 2026, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6947/242_V5_Vandetanib_monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) v::RET Medullary Thyroid Cancer Vandetanib